SERUM SOLUBLE INTERLEUKIN 2 RECEPTOR IN HYPERTHYROID Graves'DISEASE AND EFFECT OF CARBIMAZOLE THERAPY

Publisher Website
Google Scholar
Abstract
To study the activation of T lymphocytes in hyperthyroid Graves'disease, the serum concentrations of soluble interleukin 2 receptors (sIL2R) were determined during active thyrotoxicosis and following the return to a euthyroid state with carbimazole therapy. Serum sIL2R was measured by an enzyme linked immunoassay. The mean |Mp SD serum sIL2R concentration during untreated hyperthyroidism was elevated as compared with controls (919.1 |Mp 523.4 vs 374.2|Mp 189‐4 U/ml, Pr= 0.678, P < 0.01). Our study suggests that in‐vivo measurement of serum sIL2R released from activated T lymphocytes is a useful immunological indicator of disease activity.